diagnosis is delayed and there is no aggressive treatment after the diagnosis. 1, 3, 4, 12, 13 The standard treatments, including whole brain irradiation, intrathecal chemotherapy and other palliative modalities, have proven to be more effective in MC from breast cancer than in MC from lung cancer. 3, 5, 14 The survival not only depends on prompt diagnosis and treatment of MC, but also the general condition of the patient. [14] [15] [16] Previous reports of MC mainly discussed the overall features of MC from different solid tumors, including breast cancer, lung cancer, melanoma, etc. [1] [2] [3] [14] [15] [16] However, the clinical features of MC exclusively in lung cancer patients have not been well identified and characterized. The purpose of this report is to present the clinical features, laboratory findings, treatment and survival of 34 patients with MC from lung cancer in the past 11 years at a medical center.
Methods
We reviewed all cases of malignant CSF cytology at the National Taiwan University Hospital be- 
Statistical analysis
The duration of survival was measured from the date of the diagnosis of MC to death. The survival data was followed up and updated to the present time. Survival curves were plotted using the KaplanMeier method and examined by the log-rank test. The statistical significance level was set at p < 0.05 in a two-tailed test. Statistical analysis was performed using SPSS version 11.0 (SPSS Inc., Chicago, IL, USA). 
Results

Patients
CNS manifestations and CSF examinations
Thirteen patients (38%) had either concurrent radiographic evidence or a history of brain metastases. Three patients had concurrent diagnosis of brain metastases and MC at the same time. Ten patients had a history of brain metastases and nine of them had received whole brain irradiation before the diagnosis of MC. The most common neurologic symptoms before the diagnosis of brain metastases and MC were the same, including disturbance of consciousness, followed by headache and vomiting. Twenty-one patients without evidence of brain metastases reported headache as the most frequent neurologic symptoms, followed by unstable gait and disturbance of consciousness. MC produced the first symptoms of the primary tumor in nine patients (26%) and led to the diagnosis of lung cancer. The median duration of neurologic symptoms at presentation was 42 days, with a range of 8-265 days. The presenting neurologic symptoms and signs are summarized in Table 2 . The signs and symptoms were clinically localized to two levels of the neuraxis in 17 patients (50%) and involved all three levels in only five patients (15%). CSF cytology revealed adenocarcinoma in 32 patients, and squamous cell carcinoma and small cell carcinoma in one each. The opening pressure was elevated above 160 mmH 2 O in 18 of 23 patients (74%) in whom it was recorded. Overall, 35% of 23 patients had a leukocyte count above 5/μL. There were 44% of 25 patients with glucose concentrations below 45 mg/dL. The protein concentrations were elevated above 0.05 g/dL in 69% of 26 patients.
Treatment response and survival
Because of neurologic instability, systemic disease or infection, 10 patients received supportive care, seven patients received VP shunt implantation and one received three doses of 12 mg IT-MTX. Sixteen patients received whole brain irradiation including three with a VP shunt, three with IT-MTX and two with systemic chemotherapy. Only 10 patients (62.5%) completed more than 12 fractions of whole brain irradiation and only one patient (33.3%) received more than three doses of IT-MTX. All 16 patients who received whole brain irradiation tolerated it well and no infection occurred in any of the 10 patients who underwent VP shunt implantation. One patient suffered a seizure after the first dose of IT-MTX. No other complication occurred with IT-MTX treatment. Improvement was noted in seven patients during the first 4 weeks of treatment. Among them, six received whole brain irradiation (including two combined VP shunt implantation and two combined IT-MTX) and one received VP shunt implantation only. Two patients who survived the first 8 weeks after diagnosis and whole brain irradiation for MC received systemic chemotherapy (standard cisplatin plus gemcitabine regimens) for stage IV lung cancer. They were followed-up for more than 1 year. One of the patients died because of septic shock 76 weeks after diagnosis of MC and the other died because of neurologic complications 82 weeks after diagnosis of MC. All patients died during the follow-up period. The overall median survival was 5.1 weeks. Survival curves for all patients, based on treatment with whole brain irradiation (including combination therapy) and treatment without whole brain irradiation, are presented in the Figure. Median survival times for whole brain irradiation and other treatments were 5.6 weeks and 2.9 week, respectively. There was no significant difference in survival curves between those with whole brain irradiation and without whole brain irradiation (p = 0.202, log-rank test).
Discussion
Leptomeningeal metastasis, once thought to be a rare neurologic complication of solid tumors, has shown an increase in frequency over the past decades. 15, 18 We also observed an increased incidence of MC in our lung cancer patients from 1992 to 2002. This could be matched to the increasing number of lung cancer patients, the increasing incidence of leptomeningeal metastasis in lung cancer patients with longer survival after systemic chemotherapy, and the increasing awareness of this disease. However, previous reports indicated leptomeningeal metastasis occurred in approximately 5% of patients with breast cancer and non-small cell lung cancer. 15, 16, 19, 20 The incidence was higher in patients with small cell lung cancer (9-25%) and melanoma (23%). 6, 7, 20 The clinical presentation before the diagnosis of MC in our study was similar to previous reports in patients with a solid tumor with MC. 3, 16, 19 There was no difference in the symptoms and signs of those patients with MC and those with brain metastasis in our study. Therefore, headache and disturbance of consciousness should raise the suspicion not only of brain metastasis but also of MC in lung cancer patients. The interval between the diagnosis of the primary tumor and MC is quite different in patients with breast cancer and lung cancer. Sudo et al reported that the time from the date of diagnosis of lung cancer to the date of diagnosis of MC ranged from −2 days to 8 years (median, 407 days). 21 Boogerd et al reported that the diagnostic interval between breast cancer and MC ranged from 3 months to 19 years (median, 38 months). 16 The duration of the diagnostic interval in our study is very similar to other lung cancer patients but is quite different from breast cancer patients. This could be due to longer survival time in breast cancer patients than in lung cancer patients. In our study, adenocarcinoma comprised most of the CSF cytology findings. This is unique from previous reports. 3, 5, 14 This may be due to the relatively small number of cases of small cell lung cancer in Chinese compared with Caucasians. 22 Radiation therapy directed to the sites of major clinical involvement and intrathecal chemotherapy were thought of as treatment protocols for MC from a solid tumor. 3, 14, 23 However, such therapies were less effective in treatment of MC from lung cancer. 5, 19 Because the clinical presentations before the diagnosis of MC and brain metastasis were the same, lumbar puncture was essential to confirm the diagnosis of MC because whole brain irradiation could not prolong survival in patients with MC from lung cancer. Four of six patients with improved neurologic conditions also had other treatment modalities including VP shunt implantation and IT-MTX. VP shunt implantation was thought to be a palliative treatment in combined modality therapy for MC, 24 especially for those who had received whole brain irradiation for brain metastasis before the diagnosis of MC.
Intrathecal chemotherapy with gemcitabine might prove to be more suitable for MC induced by lung cancer as in case reports and such therapy is worth further study. 25 The most documented article regarding combined modality therapy for MC due to non-small cell lung cancer is that of Chamberlain and Kormanik, a study of 32 patients with a median survival of 5 months (range, 1-12 months). 19 The study was prospective and patients with poor performance status were excluded. Similar to previous studies, Chamberlain and Kormanik used intrathecal chemotherapy as a standard treatment for all 32 patients with MC. In addition, 16 patients received radiation therapy and 12 had concurrent brain metastasis. 19 Perhaps the study design could account for the longer survival in their study. The median survival rate in our study was considerably shorter than another retrospective study of 37 Japanese patients with lung cancer and MC (5.1 weeks and 15.1 weeks, respectively). This could be due to the fact that gefitinib was most often used for therapy after the onset of MC in the study. 21 Both our data and that of Sudo et al indicated that lung cancer patients with MC could survive for longer than 1 year. It is possible, if patients survive the initial neurologic complications from MC, that they still have a chance to battle lung cancer with chemotherapy or gefitinib/ erlotinib target therapy and have longer survival. Therefore, whole brain irradiation plus another treatment modality such as intrathecal chemotherapy or VP shunt implantation could be essential to treat MC from lung cancer. There were several limitations in this study. First, it was a retrospective study of therapeutic outcome and selection bias remains a potential source of error. Second, the number of patients was small and mainly limited to lung adenocarcinoma with MC. Third, the most advanced therapies were not included in our study such as intrathecal gemcitabine chemotherapy and gefitinib/erlotinib target therapy for lung cancer with MC. Therefore, a prospective study would be necessary to establish the effectiveness of combined modality therapy. In conclusion, the prognosis of MC from lung cancer is poor. Although MC is a rare complication of lung cancer in Taiwan, the clinical presentation of MC and brain metastasis are the same and MC could be easily missed if there is no further investigation to confirm the diagnosis of MC. Because whole brain irradiation could not prolong survival in patients with MC from lung cancer, combined modality therapy including whole brain irradiation, intrathecal chemotherapy and VP shunt implantation could be essential to treat patients with MC from lung cancer. Those who survive the neurologic complications from MC could have more chance of treatment for lung cancer with chemotherapy or target therapy.
